Clinical Trial Update: Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of vorinostat plus low-dose cytarabine for high-risk myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Vorinostat (vorinostat)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED